Advertisement

Orphan Drug Outlook and the Management of These Agents

The U.S. Food and Drug Administration (FDA) currently has about 200 pending orphan drug designation requests, according to experts at a session on the...

Substantial Costs Associated with Acute Bleeding Events in Hemophilia A

Information on costs related to the treatment of acute bleeding events in patients with hemophilia A is lacking, so researchers evaluated the healthcare resource...

Economic Burden is Higher for Patients with Type 2 Diabetes and Comorbidities

Patients with type 2 diabetes can experience comorbidities that lead to hospitalizations and impact the economic disease burden. Researchers sought to estimate incremental all-cause healthcare...

Lessons Learned in Value-Based Contracts

Interest in value-based contracts continues to grow, but the most of these arrangements are not publicly known. A survey of 11 pharmaceutical manufacturers and...

Gene Therapy Management in Europe Versus the United States

The United States and Europe face many similar challenges in the management of gene therapies, including high upfront costs and the logistics of getting...

Optimizing Payer and Manufacturer Communication

The legislative and regulatory environment governing proactive communication between manufacturers and payers continues to evolve, according to experts at the AMCP Annual Meeting. Insights and...

Marketplace Trends: Specialty Spending, Generics and Biosimilars, Medication Adherence, and More

Total spending on medicine in the United States was $435 billion in 2017, with a growth of only 1.4%. Specialty growth is outpacing traditional...
Advertisement